Effect of Interferon Alpha on Chronic Hepatitis C in Patients with Chronic Renal Failure and Renal Allograft Recipients.
- Author:
Young Ok KIM
1
;
Joo Hyun PARK
;
Chul Woo YANG
;
Yong Soo KIM
;
Young Min PARK
;
Yoon Sik CHANG
;
Yong Bok KOH
;
Byung Kee BANG
Author Information
1. Department of Internal Medicine, Medical College, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
End stage renal failure;
Dialysis;
Renal transplantation;
Chronic hepatitis C;
Interferon alpha
- MeSH:
Allografts*;
Dialysis;
Epistaxis;
Hematuria;
Hepatitis C, Chronic*;
Hepatitis, Chronic*;
Humans;
Interferon-alpha*;
Interferons*;
Kidney Failure, Chronic*;
Kidney Transplantation;
Liver;
Renal Insufficiency;
RNA
- From:The Journal of the Korean Society for Transplantation
1997;11(2):301-308
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Chronic hepatitis C is common complication in patients with end stage renal failure and relative contraindication to renal transplantation due to risk of progression. Although interferon alpha (IFN) treatment is proven to be effective in chronic hepatitis C with normal renal function, its effect on the treatment of chronic hepatitis C in dialysis patients and renal allograft recipients is not clear. We studied this study to evaluate the effect of IFN on chronic hepatitis C in patients with chronic renal failure and renal allograft recipients. Four dialysis patients and 2 renal allograft recipients were included in this study. The patients received IFN 3 million units three times a week for 6 months. All patients with showed normal levels of liver enzymes and seronegative conversion of HCV RNA. But seropositive conversion of HCV RNA was observed 1 dialysis patient after stopping of IFN treatment due to gross hematuria and epistaxis. Two dialysis patients had successful renal transplantation, and liver enzyme levels were normal and HCV RNA was negative after 2 months. In conclusion, IFN treatment is not only effective on the treatment of chronic hepatitis C in dialysis patients and renal allograft recipients but also may offer the potential of making transplantation a feasible option for chronic hepatitis C patients with end stage renal failure.
